Physician profile
Gary M Snyder
NPI 1427016500
$8,479.73
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,454 · 2020: $434 · 2021: $1,218 · 2022: $503 · 2023: $993 · 2024: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $4,498.13 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $801.03 | 2019-2024 | Dupixent |
| Genzyme Corporation | $629.71 | 2019-2024 | |
| Glaxosmithkline, LLC. | $529.19 | 2019-2024 | Nucala |
| Stryker Corporation | $521.97 | 2019 | |
| Alk-Abello, INC | $449.10 | 2019-2022 | |
| Kaleo, INC. | $209.17 | 2020-2022 | |
| Neurent Medical Limited | $171.62 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Aerin Medical INC. | $169.73 | 2021-2022 | |
| Inspire Medical Systems, INC. | $150.10 | 2023 | Inspire |
| Amgen INC. | $104.85 | 2021-2024 | Tezspire |
| Hikma Pharmaceuticals USA | $42.37 | 2023-2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $38.89 | 2023 | |
| Novartis Pharmaceuticals Corporation | $37.16 | 2019-2021 | |
| Glenmark Therapeutics INC. | $25.00 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.64 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.49 | 2023 | Fasenra |
| Acclarent, INC | $20.78 | 2019 | |
| Pfizer INC. | $19.25 | 2020 | |
| Abbvie INC. | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.